UCB’s Bimekizumab Gets Fast-Track Funding For Severe Psoriasis In England
New HTA Route For “Low-Risk” Products Offers Rapid Patient Access
It may not yet be approved for marketing, but UCB’s potential blockbuster psoriasis drug has already got the all-clear from NICE, the health technology body that appraises new products for use in England and Wales.
